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Introduction
 Congenital abnormalities have a major impact on neonatal morbidity / 
mortality as well as a heavy emotional burden on the family. To identify 
them prenatally is an essential task of the obstetrician, who is involved in 
the care of the pregnant women. 
Prenatal  diagnosis  is  the  art  and  science  of  identifying  structural  and 
functional abnormalities which includes screening methods and definitive 
diagnostic procedures. Screening identifies individuals whose risk is high 
enough  that  they  could  benefit  from  further  evaluation.  Screening 
methods  include  assessment  of  serum  markers  like  AFP,  hCG,  UE3, 
inhibin A, PAPP-A, and USG assessment of congenital anomalies.
Definitive diagnostic procedures include amniocentesis, CVS, fetal blood 
sampling, and Preimplantation genetic diagnosis which allows analysis of 
embryonal   and   fetal  cells  or  tissues  for  chromosomal,  genetic  and 
biochemical abnormalities.
Maternal serum alpha feto protein is a simple and cost effective screening 
method. Though initially discovered to identify neural tube defects three 
decades  ago,  studies  have  documented  that  the  values  of  MSAFP 
estimation  extends  well  beyond  the  detection  of  NTD  in  the  fetus 
[Thomas  and  Karim  1990].Abnormally  elevated  and  low  levels  of 
MSAFP  are  an  indication  of  high  risk  pregnancy  and  sub  optimal 
outcome of the pregnancy [Burton 1998, Burton et al 1983, 1986].
Before screening, the patients should receive counseling which includes 
the purpose of the tests, the risks involved, limitations of the screening 
tests and the patient’s options.
The implications of early detection of abnormalities include 
• Emotional preparation of the couple
• Elective termination of  the affected fetus
• Enable  clinician  to  provide  more  intense  obstetric  care  and 
optimize labour and delivery of the affected patients.
• To reduce the birth prevalence of severely affected fetuses.
Review of Literature
• In 1956- AFP was discovered by Bergstrand and Czar. It is the first 
major  protein  component  to  appear  in  fetal  serum.  AFP  is  a 
glycoprotein similar to albumin in structure and molecular weight. It is 
first made in the fetal yolk sack at four to eight weeks. As the yolk sac 
degenerates  by eleven weeks,  fetal  liver  takes over the function of 
producing  the  AFP.  Genes  encoding  AFP  are  in  the  long  arm of 
chromosome 4. Function of AFP is unknown although an immune / 
carrier function has been suggested. Fetal serum AFP increases in first 
trimester rising from the sixth week, reaches a peak value of 3mg/ml 
at  thirteen  weeks.  Production  of  AFP  by  fetal  liver  continues  to 
increase up to twenty weeks and there after  remain  constant  up to 
thirty two weeks due to the disproportionate increase in fetal growth. 
After thirty two weeks, production falls sharply and fetal serum AFP 
falls rapidly [GETLIN and BORMAN 1960]. Fetal serum AFP enters 
amniotic  fluid  largely  via  fetal  urination  after  renal  infiltration. 
AFAFP rises until approximately 12 weeks and there after declines. 
AFP diffuses across the placenta [2/3] and amnion [1/3] to reach the 
maternal serum. Amniotic fluid to maternal serum level ranges from 
100: 1 to 200:1. MSAFP value ranges from mg/ml in fetal serum to 
µgm/ ml in amniotic fluid to ng/ml in maternal serum. 
AFP in Normal Pregnancy
• Origin  and  regulation  of  AFP  depends  on  the  rate  of  synthesis  , 
catabolism  of  AFP  by  the  fetus,  changes  in  permeability  of  feto 
maternal barrier, volume of body fluid , disturbance in circulation of 
body fluids  and  feto  maternal  transfusion  [  Sappala  1973,  Ishguno 
1973, Wald et al 1975, Brock 1976, Getlin 1975].
• Open  neural  tube  defects  have  a  thin  covering  or  only  a  thin 
membrane  over  the  brain  /  spinal  cord,  so  AFP  can  leak  to  the 
surrounding amniotic fluid and secondarily in to the maternal serum.
• In  1972  Brock  and  Sutcliffe  showed  that  AFAFP  are  higher  in 
pregnancies with fetal anencephaly.
• In 1973 Brock and Associates showed that MSAFP are also elevated 
in affected pregnancies.
• 10 to 15% of spinal NTD, 1 % of anencephaly, 50% of encephalocele 
are skin covered and do not leak AFP and hence are not associated 
with increased MSAFP.
• In  1977  First  UK  collaborative  study  developed  the  mathematical 
principles of screening and presented a rational system upon which 
screening policy decisions are based. It also defined the optimal time 
of gestation for screening [16 – 18 weeks] and then the boundaries 
beyond  which  screening  is  either  ineffective  [<  15  weeks]  or  not 
feasible [> 22 weeks].
• In  1984,  Merkatze  et  al  showed  that  MSAFP  averaged  lower  in 
pregnancies affected by Down syndrome. It was confirmed by other 
studies- Clarke and colleagues [1984], Haddow and associates [1983].
• In 1986-1987 a multi center intervention trial of combining maternal 
age and MSAFP to screen for Down syndrome in women < 35 years 
in  the  state  of  Lowa,  showed  a  detection  rate  of  25%  for  Down 
syndrome. 
• In  1987  Bogart  and  colleagues  and  in  1988  Wald  and  associates 
showed that hCG and estriol can also be used for screening for Down 
syndrome.  
• In 1988 a large case controlled study which simultaneously examined 
AFP, uE3 and hCG and determined that the three bio chemical markers 
are  independent  of  maternal  age  and  largely  independent  of  each 
other. 
• Thus  MSAFP  screening  became  the  framework  on  which  other 
pregnancy screening tests were added.
• Several large studies have documented increased perinatal morbidity 
and  mortality  including LBW,  Oligohydramnios,  preterm birth  and 
fetal  death in patients with unexplained elevated MSAFP. Some of 
them are
• Simpson and colleagues [1991] in their study reported that there was a 
significant  association  between  second  trimester  elevated  AFP and 
PPROM, preterm labour and LBW. 
• Ramus  and  associates  [1996]  reported  an  increased  incidence  of 
preterm delivery in women with unexplained serum AFP elevation. 
• In 1994 Reicheler and colleagues reported that there was a progressive 
increase in frequency of NTD, ventral wall defects and fetal anomalies 
as a direct function of maternal serum level. 
• In  1996  ACOG  recommends  that  all  pregnant  women  be  offered 
second trimester MSAFP screening as 90 to 95 % of infants with NTD 
are  born  to  families  with  no  history  of  NTD  and  85%  of  Down 
syndrome is born to women < 35 years.  
Laboratory Aspects of MSAFP 
1. Normative data should be established for the population served by 
the laboratory.
2. Assay precision and accuracy must be monitored.
3. Precision  refers  to  the  coefficient  of  variation  when performing 
replicate tests on the same samples.
4. Accuracy  refers  to  the  laboratory  result  compared  to  a  known 
external standard.
5. Factors influencing MSAFP levels should be corrected.
Factors Influencing MSAFP values 
• Gestational  age:  MSAFP  steadily  increases  about  15%  /  week 
during the second trimester. MSAFP continues to rise (in contrast 
to fetal AFP) until 30 to 32 weeks before declining. 
• Race: MSAFP is 10 to 15% higher in black women.
• Maternal weight: MSAFP value is lower in heavier woman because 
of dilution effect.
• Multiple  gestation:  Levels  increase  due  to  increased  number  of 
fetuses and the cut off for elevated value is twice than normal.
• IUD: Levels increase due to disruption of placental barrier.
• IDDM: IDDM is associated with MSAFP that averages 40% lower 
than general pregnant population. 
MSAFP ESTIMATION
Principles of the Assay
The  essential  reagents  required  for  an  immunoenzymometric  assay 
include high affinity and specific antibodies, with different and distinct 
epitope recognition, in excess and native antigen. In this procedure, the 
immobilization takes place during the assay at the surface of a microplate 
well  through  the  interaction  of  streptavidin  coated  on  the  well  and 
exogenously added biotinylated monoclonal anti –AFP antibody.
Upon  mixing  monoclonal  biotinylated  antibody,  the  enzyme  labeled 
antibody  and  a  serum  containing  the  native  antigen  reaction  results 
between the native antigen and the antibodies,  without  competition or 
steric hindrance, to form a soluble sandwich complex.  Simultaneously, 
the complex is deposited to the well through the high affinity reaction of 
streptavidin and biotinylated antibody.
After  equilibrium is  attained,  the antibody-bound fraction  is  separated 
from unbound antigen by decantation or aspiration. The enzyme activity 
in  the  antibody-bound  fraction  is  directly  proportional  to  the  native 
antigen concentration. By utilizing several different serum references of 
known  antigen  values,  a  dose  response  curve  can  be  generated  from 
which the antigen concentration of an unknown can be ascertained.
Materials Provided in the Kit
1. Alpha fetoprotein(AFP) - 1 ml/vial
• Six vials of references AFP antigen at levels of 0, 5, 25, 50, 250 
and 500 ng /ml.
2. Anti-AFP Enzyme reagent - 13 ml/vial 
• One  vial  containing  enzyme  labeled  antibody,  biotinylated 
monoclonal IgG
3. Streptavidin Coated microplate - 96 wells.
• One 96 – well microplate coated with streptavidin
4. Wash solution concentrate - 20 ml 
• One vial containing a surfactant in buffer.
5. Substrate A - 7 ml/vial
• One bottle containing tetra methyl benzidine in buffer.
6. Substrate B - 7ml/vial
• One bottle containing hydrogen peroxide in buffer.
7. Stop solution - 8 ml/vial
• One bottle containing a strong acid (1N HCl).
Storage and Stability
• The kits should be stored at 2 to 8oC and micro well is kept in a dry 
bag with desiccants.
• Solution A and B should be colourless: If the solution turns blue it 
must be replaced. These reagents should not be exposed to strong 
light during storage or usage.
Specimen Collection and Handling
The blood is collected by venipuncture, allowed to clot and the serum is 
separated  by  centrifugation  at  room  temperature.  If  sera  cannot  be 
assayed immediately, they can be stored at 2 to 8oC or frozen.
Preparation for Assay
• All reagents and samples are brought to room temperature (20 to 
25oC) and gently shaken before beginning the test.
• All  reagents  and samples  are  kept  ready  before  the start  of  the 
assay. Once the test  is started it must  be performed without any 
interruption to get the most reliable and consistent results. 
• New disposable tips are used for each specimen.
Assay Procedure 
1. The microplate wells for each serum reference, control and patient 
specimen to be assayed in duplicate are formatted.
2. 25 µl of the appropriate serum reference, control or specimen is 
pipetted out into the well.
3. 100 µl of the anti –AFP Enzyme reagent is added to each well.
4. The microplate is swirled gently for 20—30 seconds.
5. Incubation is done for 60 min at room temperature.
6. The  contents  of  the  microplate  are  discarded  by  decantation  or 
aspiration.
7. 300  µl  of  wash  buffer  is  added  and it  is  used  in  an  automatic 
washer and a total of three washes given.
8. 100 µl of the working substrate solution is added to all wells.
9. Incubation is done at room temperature for 15 minutes.
10.50 µl of stop solution is added to each well and mixed gently for 15 
to 20 seconds.
11.The absorbance in each well  is  read at  450 nm in a microplate 
reader.
Calculation of results
1. The concentration (X) of each reference standard is plotted against 
its absorbance (Y) on full log arithmic graph paper
2. AFP value of the patient is obtained by referring to the standard 
curve
MSAFP is measured in ng/ml. Normal non pregnant adult serum AFP is 
< 10 ng/ml. In pregnant women MSAFP value increases with advancing 
gestation to approximately 30 weeks, then plateaus until 36 weeks and 
then falls.
MSAFP  value  in  pregnancy  is  expressed  as  MOM  of  the  unaffected 
population. MOM is obtained by dividing an individual’s MSAFP value 
by  the  median  for  the  relevant  gestational  week.
Using the MOMs to normalize AFP values
1. Allows information from different laboratories to be interpreted in 
a common manner.
2. Normalizes rising MSAFP and reducing AFAFP during the period 
of screening.
3. Can be readily  adjusted for  variables  which affect  AFP such as 
diabetes, weight and race.
4. It also provides a more precise parameter for setting screening cut 
off as opposed to standard deviation and percentile rate.
Normal range of MSAFP Value 0.5 to 2.5 MOM
Cut off values for Elevated 
MSAFP value ≥ 2 to 2.5 MOM
Cut off values for Low MSAFP 
value ≤ 0.5 MOM
Cut off values in Multiple 
pregnancy ≥ 4.5 to 5.0 MOM (twice than normal)
Cut off values in IDDM ≥ 1.5 MOM ( 40 % lower than general population)
Distributions  of  serum  AFP  overlap  in  affected  and  unaffected 
pregnancies. If the level is within the range of overlap, the indiscriminate 
zone of 2.5 to 3.5 MOM, then repeating measurement may determine to 
which distribution the sample actually belongs – affected / unaffected.
The cut off value of 2.5 multiples of the median results in both false – 
positive (cross hatched area) and false negative diagnosis.
If  MSAFP is  ≥ 3.5 MOM then measurement  need not  be repeated as 
levels this high are outside AFP distribution of unaffected pregnancies 
and associated with increased fetal risk. 
Follow Up of Patients with Abnormal MSAFP
Conditions associated with elevated AFP levels
1. Neural tube defects
2. Pilonidal cysts
3. Esophageal or intestinal obstructions
4. Liver necrosis
5. Cystic hygroma
6. Sacrococcygeal teratoma
7. Abdominal wall defects – omphalocele, gastroschisis
8. Urinary obstructions
9. Renal anomalies – Polycystic or absent kidney 
10.Congenital nephrosis
11.Osteogenesis imperfecta
12.Congenital skin defects
13.Cloacal exstrophy
14.Amniotic band disruption
15.Fetal growth restriction and death
16.Fetomaternal haemorrhage
17.Preterm membrane rupture and delivery
18.Chorioangioma
19.Low birth weight
20.Oligohydramnios
21.Multifetal gestation
22.Decreased maternal weight
23.Underestimated gestational age
24.Maternal  hepatoma  or  teratoma,  acute  viral  hepatitis,  lupus 
antibody.
Conditions associated with low AFP levels
1. Chromosomal trisomies
2. Gestational trophoblastic disease 
3. Fetal death
4. Increased maternal weight
5. Overestimated gestational age
Using a MSAFP level  of  2 to 2.5 as the upper limit  of  normal,  most 
laboratories report
• Screen positive rate of 3 to 5 %
• Sensitivity of 90%
• Positive  predictive  value  of  2  to  6% (  Milunsky  and associates 
1989)
But  the main  problem is  that  MSAFP testing has a  high rate of  false 
positives. Only a small fraction of those patients with abnormally high or 
low MSAFP values will actually have affected babies. 
Burton et al found only 15 out of 452 women with abnormal MSAFP 
actually had affected fetus. 
Simpson et al found only 1 out of 187 women with abnormal MSAFP had 
an affected fetus. 
Therefore  it  is  necessary to follow a series  of steps in the analysis of 
patients with increased or decreased MSAFP values to avoid an in correct 
diagnosis.
Recommendations for follow up of patients with elevated 
MSAFP 
MSAFP values above 2.5MOM are considered abnormal. When a patient 
has an elevated MSAFP level, an USG (Level—1) should be performed. 
USG can detect most common non genetic reasons causing high MSAFP 
values. An elevated MSAFP may result from an error in the dating of the 
pregnancy. A high value may become normal when an underestimated 
gestational age is corrected .20 to 25% of patients with elevated MSAFP, 
when reassigned to correct GA, will not need further testing.
Other  conditions  associated  with  elevated  MSAFP  which  can  be 
diagnosed by an USG (Level-1) include
• Multiple gestation in 15% of cases
• Undiagnosed fetal demise in 5% of cases
• Severe oligohydramnios
• Obvious anatomical defects in 2 to 3% of cases
• Other  rare  conditions  like  fetal  hydrops  which  cause  elevated 
MSAFP
After a level I USG has ruled out the above conditions, a level II 
USG is done. If it is normal, then further management depends on the 
level  of  elevated MSAFP Amniocentesis  is  definitely  recommended if 
level is > 3 MOM.
Level II Ultrasound
Normal Ultrasound 
Adequate dates
Normal
MSAFP 2.5 to 2.9 MOMs MSAFP > 3.0 MOMs
Reassured Amniocentesis 
offered
Amniocentesis recommended
Level 1 Ultrasound Error in dates 
Multifetal pregnancy
Unrecognized fetal demise
Obvious malformation
Severe oligohydramnios
Fetal hydrops
Abnormal
The objective of genetic amniocentesis in patients with elevated MSAFP 
is to determine the concentration of AFP in the amniotic fluid .AFAFP 
determination  is  a  diagnostic  test,  in  contrast  to  MSAFP  which  is  a 
screening test.
AFAFP
Normal Elevated
No need for further 
testing
Patient informed of the 
adverse obstetric 
outcome in 
unexplained elevations 
of MSAFP
Amniotic fluid acetyl 
cholinesterase
Amniotic fluid acetyl 
cholinesterase
Elevated
Normal
Patient reassured 
Elevated AFP probably
caused by fetal blood 
contamination
High risk for pregnancy 
complications
Repeat Level II 
ultrasound
Repeat 
amniocentesis
Normal
Elevated AFP, acetyl 
cholinesterase (+)
Probability of open 
NTD is > 1:10
Normal AFP acetyl 
cholinesterase (-)
Patient Reassured
NTD or abdominal wall defect 
identified
 In most  centers,  chromosome analyses are performed on all  amniotic 
fluids obtained because of elevated MSAFP levels. When AFAFP level is 
elevated, chromosome analysis is of value, since a significant proportion 
of  fetuses  with  NTD  also  have  chromosomal  abnormalities.  Also 
knowledge of the karyotype may be important  for  parents  considering 
termination of pregnancy.
Unexplained elevations of MSAFP
Elevated MSAFP with normal  USG and normal  level  of  AFAFP will 
forecast  a  poor  pregnancy  outcome,  even  with  no  obvious  fetal 
anomalies. Increased perinatal morbidity and mortality including LBW, 
oligohydramnios,  placental abruption, preterm birth and fetal  death are 
noted. 
The placenta either secondary to providing increased areas of transport or 
in providing an abnormal endothelial barrier provides for greater transfer 
of fetal serum AFP and thus AFAFP in to the maternal compartment. An 
abnormal placenta is also a likely explanation for the increased risk of 
adverse pregnancy outcome that is associated with increased MSAFP for 
which no etiology is found 
Therefore  knowledge  of  increased  MSAFP  unassociated  with  fetal 
structural malformations should trigger a modification of prenatal care to 
provide enhanced fetal and maternal surveillance
Recommendations for Patients with low MSAFP levels
After correcting for the low MSAFP value for weight, presence of IDDM 
and the race to which the patient belongs, an USG is done to correct GA 
and rule out missed abortion /blighted ova.
If still  the MSAFP value is  found to be less than 0.25 MOM, genetic 
amniocentesis is done for karyotyping, as MSAFP on average is 25% less 
in trisomies than the level in women with chromosomally normal fetus 
and is not dependent on age. Down syndrome risk increases steadily but 
slowly in relation to a woman’s age until mid thirties after which the risk 
increases  at  an  accelerated  pace.  AFP  levels  in  affected/  unaffected 
population are independent of her age, hence both can be combined to 
derive a risk and increase the overall screening efficiency rate. 
When  maternal  age  alone  is  used  a  screening  factor  31%  of  Down 
syndrome is detected , with a false positive rate of 7.5% .When MSAFP 
estimation  is  done  in  women  <35  years,  detection  rate  for  Down 
syndrome is 25 – 30% . 
Specific fetal aneuploid conditions commonly detected through maternal 
serum analyte screening include Down and Edward syndrome. Evidence 
indicates  that  the  measurement  of  AFP  in  maternal  serum  can 
discriminate chromosomal anomalies as early as 9 to 11 weeks gestation. 
MSAFP screening became the frame work upon which other pregnancy 
screening tests were added. It was discovered that hCG in maternal serum 
to average more than 2 times higher in Down syndrome and uE3 was 
reported to average 25% lower in Down syndrome .Combining all  the 3 
tests,   80%  of  all  autosomal  trisomies  are  detected.  When  all  three 
markers are combined to screen, it is called triple test .Recently dimeric 
inhibin A is added to the list and it is called Quad screen. 
When karyotyping is normal in the presence of low MSAFP there is 30% 
probability of an abnormal outcome of the pregnancy like spontaneous 
abortion, fetal death, hydatiform mole and choriocarcinoma. 
Screening Protocol for patients with Low MSAFP
15 – 20 Week
Maternal Serum
Sample
Risk ≥ 1:270 Risk 1 < 270
USG to verify 
gestational age
GA < 15 weeks by 
scan.
Genetic counseling
Amniocentesis.
Scan differs from 
LMP by 10 – 14 
days.
Repeat sample at 16 
weeks
Gestational dating 
verified
GA ≥ 15 weeks by 
scan.
Recalculate down 
syndrome risk.
If Risk < 1:270 then 
No further Testing
If Risk > 1:270 then 
Genetic counseling
Amniocentesis
Aim of the study 
To evaluate the usefulness of Maternal Serum Alpha Feto Protein 
estimation as a screening method to identify the mothers at risk of 
• Neural tube defects
• Other congenital anomalies
• Chromosomal abnormalities
• Other  adverse  pregnancy  outcomes  such  as  LBW,  IUGR, 
spontaneous  abortion,  preterm  birth,  still  birth  and  neonatal 
complications,  so  that  effective  and timely  therapeutic  measures 
can be taken to modify the fetal outcome
Materials and Methods
Study  is  carried  out  in  Government  RSRM hospital,  Stanley  Medical 
College, during the period from December 2004 – January 2006
Study group comprised of 75 cases of pregnant patients at GA 15 to 22 
weeks who attended our antenatal OPD with any one of the following 
high risk factors
1. Age above 35 years
2. Previous H/O early pregnancy loss
3. Previous H/O congenital anomalies
4. Previous H/O neural tube defects
5. Previous H/O baby with Down Syndrome
6. Family H/O congenital anomalies/ chromosomal disorder
7. Known epileptic patient on treatment
8. Anemia complicating pregnancy
9. Fetuses exposed to any teratogen.
Most of the patients had regular menstrual cycles, were not on any oral 
contraceptives  and  they  knew  their  LMP  correctly.  For  patients  with 
irregular  cycles/  unreliable dates,  gestational  age was determined by a 
dating scan. 
A detailed work up of  each patient  was carried out  according to well 
designed proforma. A detailed history was taken and a thorough physical 
examination was performed.  Routine investigations included Hb, urine 
analysis, Blood Grouping/ Typing and VDRL.
For  the  subjects  in  the  study  group  blood  3cc  was  collected  by  the 
venipuncture  in  a  sterile  test  tube  and  sent  to  the  laboratory  where 
MSAFP measurement was done. The blood was allowed to clot and the 
serum was separated by centrifugation at room temperature and stored in 
-20ºC deep freezer. 
Method
Test  is  a  solid  phase  enzyme  linked  immunosorbent  assay.  This  test 
provides quantitative measurement of human alpha feto protein in serum 
and in amniotic fluid. Detailed principles of the assay of serum AFP is 
explained before in the section of laboratory aspects of MSAFP.
Calculation of Results
1. The concentration of each reference standard is plotted against its 
absorbance  on full logarithmic graph paper
2. AFP value of the patient is obtained by referring to the standard 
curve
The results obtained were compared with the standard value (in MOM) of 
the laboratory. Those patients whose MSAFP concentration was above 
2.5 MOM underwent USG. If anomalies were found, after counseling, the 
pregnancy was terminated. In case where there were no ultrasonologically 
detectable  anomalies,  cases  were  followed  up  till  the  termination  of 
pregnancy with special reference to fetal weight, gestational age, apgar 
score and perinatal outcome. 
Results
The study group consisted of 75 patients at GA 15 to 22 weeks who had 
any of the risk factors cited above. MSAFP screening was done for these 
patients and the value of MSAFP was converted from ng/ml to MOM by 
dividing the patient’s value with the mean value for the particular GA.
Values above 2.5 MOM were considered elevated and < 0.5 MOM were 
considered  low.  All  patients  were  followed  till  delivery  and  the 
pregnancy outcome was noted The relation between abnormal MSAFP 
value and adverse pregnancy outcome was correlated.
Distribution of Age Group 
Age Number of patients Percentage
16-20 4 5.33%
20-25 45 60%
26-30 16 21.33%
31-35 8 10.66%
> 35 2 2.66%
Observation 60 % of the patients lie in the 20-25 age group
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Gravidity Number Percentage
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Distribution of Patients according to Gestational Age (GA) 
GA Number Percentage
15 9 12%
16 12 16%
17 9 12%
18 7 9.33%
19 6 8%
20 11 14.66%
21 3 4%
22 18 24%
Observation Most of the patients screened were at 22 weeks, though the screening was done between 15 to 22 weeks
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Laboratory Standard Value of MSAFP for Each Week of 
Gestation in MOM
GA( weeks) Median value of MSAFP
Multiple of Median
2.5 0.5
15 11 27.5 5.5
16 14 35 7
17 20 50 10
18 27 67.5 13.5
19 35 87.5 17.5
20 42 105 21
21 50 125 25
22 60 150 30
This table shows median according to gestational age. This 
standardized mean was followed in the study.
No of cases showing elevated MSAFP level according to 
gestational age
Total Number of Cases – 75 
GA Total Number of Patients
Number of Patients 
with Elevated 
MSAFP 
Percentage
15 9 5 55.55%
16 12 4 33.33%
17 9 2 22.22%
18 7 4 57.14%
19 6 3 50%
20 11 5 45.45%
21 3 0 0
22 18 5 27.77%
Observation Out of the study group 37.33% showed elevated MSAFP value. 57.14% in the 18 weeks gestation showed elevated MSAFP level.
Patients according to high risk factor
Total Number of Cases – 75 
High Risk Factors Number Percentage
BOH 26 34.66%
Hypertension / BOH 5 6.66%
Known epileptic / BOH 2 2.66%
BOH/ Anemia 1 1.33%
Hypertension complication 
pregnancy 3 4%
Positive family history of 
Hypertension 2 2.66%
Anemia / Hypertension 2 2.66%
Anemia 6 8%
Anemia / previous history of 
anomalous baby 1 1.33%
Anemia / Positive family H/O 1 1.33%
Known epileptic on treatment 3 4%
Known epileptic on 
treatment / positive family 
history
1 1.33%
Fever 3 4%
Previous history of anomalous 
baby 6 8%
Drug intake 5 6.66%
Positive family history 6 8%
Elderly Gravida 2 2.66%
Observation Maximum number of cases screened were with history of BOH- 34.66%
Causes of Elevated MSAFP
Normal
NC
LBW IUGR
Preterm
IUD
Anomalies
EPL
Causes of elevated MSAFP in the present study
Causes Number of Cases Percentage
Anomalies 3 10.71%
Early pregnancy 
loss 2 7.14%
IUD 2 7.14%
Preterm 7 25%
IUGR 1 3.57%
LBW 5 17.85%
Neonatal 
complications 3 10.71%
Normal 5 17.85%
Type of congenital anomalies in elevated MSAFP
Total no of congenital anomalies - 3
CNS anomalies - 2
Other anomalies - 1
S.No Anomaly Number
1 Anencephaly 1
2 Spinabifida 1
3 Exomphalos 1
Association of elevated MSAFP Level and Congenital 
Anomalies
Diagnosis
MSAFP
Normal Elevated( ≥ 2.5 MOM)
Low
( ≤ 0.5 MOM)
Congenital 
Anomalies Nil 3 Nil
Observation 1. MSAFP levels are elevated in all the 3 cases of pregnancies with anomalous babies.
• Among the study group 3 (4%) had congenital anomaly.
• Among the congenital anomalies 100% had elevated MSAFP
• 10.71% of patients with elevated MSAFP had congenital anomaly.
Association of MSAFP Level and preterm deliveries
Diagnosis Number of cases
MSAFP
Normal Elevated(2.5 MOM)
Low
(0.5 MOM)
Preterm 
deliveries 8 1 7 Nil
Observation
1. Among study group 8(10.66%) went into preterm labour.
2. Out of 8 cases 7 had elevated MSAFP (87.5%) 
3. 1 patient had normal MSAFP (12.5% )
4. 25% of patients with elevated MSAFP level had preterm 
deliveries.
Association of MSAFP level and IUGR
Diagnosis Number of cases
MSAFP
Normal Elevated(2.5 MOM)
Low
(0.5 MOM)
IUGR 1 Nil 1 Nil
Observation
1. Among the study group 1(1.33%) had IUGR.
2. Hence 100% of patients with IUGR had elevated MSAFP.
3. 3.75% of patients with elevated MSAFP had IUGR.
Association of MSAFP Level and LBW
Diagnosis Number of cases
MSAFP
Normal Elevated(2.5 MOM)
Low
(0.5 MOM)
LBW excluding 
preterm 5 2 3 Nil
Observation
1. Among the study group 5(6.66%) had LBW.
2. Among the LBW 60% had elevated MSAFP.
3. 40% had normal MSAFP.
4. 10.71% of patients with elevated MSAFP had LBW.
Association of early pregnancy loss and MSAFP 
Diagnosis Number of cases
MSAFP
Normal Elevated(2.5 MOM)
Low
(0.5 MOM)
Incomplete 
abortion 2 1 1 Nil
Complete 
abortion 1 Nil 1 Nil
Observation
1. Among the study group 3 (4%) had early pregnancy loss
2. 66.66% had elevated MSAFP
3. 33.33% had normal MSAFP
4. 7.14%  of  patients  with  elevated  MSAFP  had  early 
pregnancy loss
Fetal outcome in the study group (75 Patients)
Diagnosis
Number of cases
MSAFP Level
Normal Elevated Low
No Percentage No % No % No %
Still Birth 2 2.66% - - - - - -
      Fresh 1 1.33% - - 1 100 - -
      Macerated 1 1.33% - - 1 100 - -
Neo natal death 1 1.33 % 1 100 - - - -
Anomalies 3 4% - - 3 100 - -
     CNS 2 2.66% - - 2 100 - -
     Omphalocele 1 1.33% - - 1 100 - -
Neonatal 
complications 3 4% - - 3 100 - -
This study shows 2.66% of still births in the study group .All of them 
showed elevated MSAFP levels. 
One of the still births is a macerated IUD, delivered at 7 months by a 
mother who had previous four abortions.
The other still birth is a fresh IUD delivered at 6 months, by a mother 
who was a case of severe PIH.
One neonatal death occurred but the mother had normal MSAFP value. 
The baby died of respiratory distress 2 days after delivery. Autopsy was 
not done as the parents were not willing to subject the baby for autopsy.
4% of the study group had anomalous babies out of which 66.66% had 
CNS anomalies 
(anencephaly  and  spinabifida)  and  33.33%  had  ventral  wall  defect 
(exomphalos).
Among  the  study  group  4%  had  neonatal  complications  and  all  had 
elevated MSAFP 
Pregnancy outcome in the study group of 75 patients
Outcome Number Percentage
Early Pregnancy Loss 3 4%
Congenital Anomalies 3 4%
IUD 2 2.66%
Preterm 8 10.66%
IUGR 1 1.33%
LBW 6 8%
Neonatal Complications 3 4%
Neonatal Death 1 1.33%
Normal 48 64%
Pregnancy outcome in the study group 
EPL, 3
Anomalies, 3
IUD, 2
Preterm, 8
IUGR, 1
LBW, 6
Normal, 48
NC, 3
Neonatal Death, 
1
Adverse pregnancy outcome in patients with normal 
MSAFP includes
LBW 1 2.17%
Preterm 1 2.17%
Incomplete abortion 1 2.17%
Neonatal death 1 2.17%
Relation of MSAFP Value and Pregnancy out come
MSAFP Adverse Pregnancy Outcome
Normal Pregnancy 
Outcome
Abnormal MSAFP 23 6
Normal MSAFP 4 42
29 patients had abnormal MSAFP values out of which 28 patients had 
elevated MSAFP with an adverse pregnancy outcome in 23 cases and 1 
patient had a low MSAFP but she had a normal pregnancy outcome.46 
patients had normal  MSAFP with an adverse pregnancy outcome in 4 
cases.
Sensitivity= 85.18%
Specificity = 87.5%
Positive predictive value =79.3%
Negative predictive value = 91.3%
Discussion
This study population consists of 75 pregnant high risk women between 
GA 15 to 22 weeks and were screened with MSAFP 
MSAFP level observed in the study 
MSAFP Present Study (%) Shanti Yadav et al (1993) (%)
Normal 61.33 24
Elevated 37.33 70
Low 1.33 6
MSAFP value  in  this  study  group was  normal  in  61.33% of  patients, 
elevated in 37.33% and low in 1.33%
Percentage Detection of NTD
Study Group Percentage Detection of NTD
Present study 100 %
Dipika Loghany 72.7%
In most studies ≥ 95% anencephaly, 75 to 90% of other open NTDs and 
85% of all ventral wall defects are detected. (ACMG policy statement by 
Deborah and Driscoll 2004)

Early pregnancy loss and abnormal MSAFP 
Study Group
MSAFP
Normal Elevated Low
Present Study
Incomplete 
Abortion 50% 50% Nil
Complete
abortion Nil 100% Nil
Shanthi 
Yadav et al 4.5% 72.77% 22.7%
V.K Singh et al
Incomplete 
Abortion - + -
Missed
Abortion - + -
In early pregnancy loss the MSAFP levels are elevated in about 72.72%, 
low in 22.72% and normal value in 4.5% as reported by Shanti Yadav et 
al (1993).
Other studies which showed associations between early pregnancy loss 
and abnormal MSAFP include
1. Krause et al in their study of 77,149 showed a U shaped relation, 
with both low and high MSAFP values associated with increased 
incidence of early pregnancy loss. 
• In MSAFP value < 0.25 MOM – a RR of early pregnancy loss of 
15% is seen.
• In MSAFP value >2.5 MOM – a RR of early pregnancy loss of 
12.5% is seen.
2. Vinita  Das  et  al  showed  in  her  study  that  MSAFP  level  is 
significantly elevated (P < 0.001) in patients with threatened and 
inevitable  abortion.  On  the  other  hand,  MSAFP  values  were 
significantly low (P < 0.01) in patients with missed abortion. 
Preterm deliveries and MSAFP
Study Group
MSAFP
Normal Elevated Low
Present study 12.5 % 87.5% Nil
Shanti Yadav 
et al Nil 100% Nil
Other studies correlating abnormal MSAFP and preterm birth, include 
1. Krause et al showed in his study showed a relative risk of 2.2 for 
preterm birth in MSAFP <0.25 and 4.8 for MSAFP ≥ 2.5
2. Simpson  et  al  in  his  group of  650 patients  without  neural  tube 
defects ,  noted that II  trimester  MSAFP is significantly elevated 
with PPROM and preterm birth 
3. Cusick et al in a study of 383 patients found increased incidence of 
preterm births – 14.3 % , 15.6% and 20.3% with MSAFP ranges of 
2 to 2.49 , 2.5 to 2.99 and >= 3 respectively
4. Waller  and  Cunningham  studied  records  of  51,008  women.  In 
those with elevated MSAFP , 24.3% had preterm births compared 
with 3.8% of women with decreased MSAFP
LBW and MSAFP
Study Group
MSAFP
Normal Elevated Low
Present study 16.66% 83.33% Nil
Jyotsana 
Pandy et al 39.1% 60.9% Nil
Other studies showing abnormal MSAFP and LBW include
1. Krause et al showed a relative risk of 1.4 for LBW with MSAFP < 
0.25 MOM and 5.8 with values > 2.5 MOM
2. Cuckle et al showed that 94 pregnancies without NTD , but with 
MSAFP ≥  3 resulted in LBW (P < 0.001)
3. Cusick et al in a study of 383 patients found increased incidence of 
LBW – 7.4%, 11.1% and 22.2% with MSAFP ranges of 2 to 2.49 
MOM, 2.5 to 2.99 MOM, ≥ 3 MOM respectively 
4. Simpson et al found significant elevation of MSAFP with LBW in 
a group of 650 patients
5. Milunsky et al in their study of 13,486 patients found a relative risk 
of 4 for patients with elevated MSAFP 
Still birth and abnormal MSAFP
Study Group
MSAFP
Normal Elevated Low
Present study Nil 100% Nil
Dipika 
Loghany et 
al
16.66% 77.77% 1%
Other studies relating still birth and abnormal MSAFP include
1. Krause et al in their study showed a relative risk of 3.2 for MSAFP 
value <0.25 MOM and 0.9 for MSAFP > 2.5 MOM
2. Milunsky et al showed a RR of 3.3 for still birth in women with 
abnormal MSAFP.
3. Waller  and Cunningham in their  case control study showed that 
women with highest levels of serum alpha feto protein ≥ 3 MOM 
had a very high risk of fetal death – odds ratio of 104 and those 
with 2 – 2.9 MOM had a odds ratio of 2.4 than women with normal 
MSAFP 
Neonatal complications and abnormal MSAFP
Study Group
MSAFP
Normal Elevated Low
Present study Nil 100% Nil
Shanthi 
Yadav et al 40% 60% Nil
In  the  present  study  of  75  pregnant  patients  4%  had  neonatal 
complications.  Among  the  patients  with  neonatal  complications  100% 
had elevated MSAFP compared to 60% in Shanti Yadav et al study
1. Milunsky  et  al  in  their  study  showed  a  relative  risk  of  3.6  for 
neonatal complications in case of abnormal MSAFP
Neonatal death and abnormal MSAFP
Study Group
MSAFP
Normal Elevated Low
Present study Nil 100% Nil
Jyotsana 
Pandey et al 16.66% 83.33% Nil
In the present  study 1 patient  had neonatal  death,  but  the mother  had 
normal MSAFP. 
Milunsky et al showed a relative risk of 15.9 for abnormal MSAFP. 
Summary
1. The study group comprised of  75 high risk pregnant patients in 
gestational age 15 to 22 weeks and MSAFP was estimated in all 
patients
2. MSAFP values were elevated in 37.33% ( > 2.5 MOM ), normal in 
61.33% and low in 1.33% (<0.25 MOM)
3. Ultra sonogram was done in patients with elevated MSAFP. In 3 
cases congenital anomalies were found out of which 2 (75%) cases 
of neural tube defects and 1 (25%) case of omphalocele was found 
and the pregnancy was terminated. Other cases were followed till 
delivery.
4. MSAFP was elevated in 100% of cases with anomalies, fetal death, 
IUGR and neonatal complications.
5. Adverse pregnancy outcomes noted were 
• Anomalies – 4%
• Early pregnancy loss – 4%
• IUD – 2.66%
• Preterm – 10.66%
• IUGR – 1.33%
• LBW (excluding preterm) –  8%
• Neonatal complications – 4%
• Neonatal death – 1.33%
• Normal outcome in  64% of cases
6. Strong associations were found between elevated MSAFP and the 
following adverse pregnancy outcomes
• Anomalies – 100%
• Preterm deliveries – 87.5%
• Early pregnancy loss – 66.66%
• LBW – 83.33%
• IUD – 100%
• Neonatal complications – 100%
• IUGR – 100%
7. This study results clearly indicate the chance of adverse pregnancy 
outcome were increased in patients with elevated MSAFP
8. The sensitivity of the screening program in this study in 85.18%, 
specificity – 87.5%, positive predictive value – 79.3% and negative 
predictive value – 92.30%.
Conclusion
The conclusion arrived from the present study are 
• This  study  indicates  an  association  between  adverse  pregnancy 
outcome and neonatal complications with elevated MSAFP.
• A  careful  antenatal  supervision  is  indicated  in  patients  with 
elevated or low level of MSAFP.
• The screening procedure helps us to offer therapeutic termination 
to patient when there is an anomalous fetus.
• Elevated MSAFP level is associated with poor fetal outcome and 
should be considered as ominous prenatal finding. 
Thus this screening procedure of MSAFP provide physician an important 
information  and  helps  physician  in  identifying  high  risk  patients  and 
providing special care and specific investigations. 
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ABBREVIATIONS
µg Micro Gram
ACOG American College of Obstetrics and Gynaecology
AFAFP Amniotic Fluid Alpha Feto Protein
AFP Alpha Feto Protein
Alb Albumin
BOH Bad Obstetric History
BPD Biparietal Diameter
C Celcius
cm Centimeter
CPD Cephalopelvic Disproportion
EPL Early Pregnancy Loss
FL Femur Length
GA Gestational Age
gms Grams
H/O History of
Hb Hemoglobin
hCG Human Chorionic Gonadotropin
IDDM Insulin Dependant Diabetes Mellitus
IUD Intra Uterine Death
IUGR Intra Uterine Growth Restriction
Kg Kilogram
LBW Low Birth Weight
LMP Last Menstrual Period
LSCS Lower Segment Caesarean Section
mg Milligram
MOM Multiples of Median
MSAFP Maternal Serum Alpha Feto Protein
NC Neo Natal Complications
ng Nanogram
NTD Neural Tube Defects
OPD Out Patient Department
PAPPA Pregnancy Associated Plasma Protein A
RR Relative Risk
RSRM Raja Sir Ramasami Mudaliar
uE3 Unconjugated Estriol
USG Ultra sonogram
VDRL Venereal Disease Research Laboratory 
